Case Report

Bilateral Deep Brain Stimulation of the Subthalamic Nuclei in Parkinson’s disease Patients with Camptocormic Posture

Fadi Almahariq¹, Marina Raguz¹*, Vladimir Vuletic², Darko Oreskovic¹, Ivica Franciskovic¹, Petar Marcinkovic¹ and Darko Chudy¹

¹Department of Neurosurgery, University Hospital Dubrava, Zagreb, Croatia
²Department of Neurology, University Hospital Center Rijeka, Rijeka, Croatia

*Address for Correspondence: Marina Raguz, Department of Neurosurgery, University Hospital Dubrava, Avenija Gojka Suska 6 Zagreb HR-10000, Croatia, Tel: +385 1 290 2476; Fax: +385 1 290 2934; E-mail: marinaraguz@gmail.com

Submitted: 05 August 2017; Approved: 17 August 2017; Published: 19 August 2017


Copyright: © 2017 Raguz M, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION

Camptocormia, also known as “Bent Spine Syndrome” (BSS), is one of the most disabling features of Parkinson’s disease (PD). It manifests as a marked forward flexion of the thoracolumbar spine that worsens during walking or standing with a tendency to worsen with fatigue [1,2], but disappears in the recumbent position [3-5]. Camptocormia occurs in approximately 10% of PD patients [2], progressively over a year or more, and the trunk flexion is usually associated with scoliosis in these patients. Long standing camptocormia often results in low back pain from sagittal misalignment and potentially increases the risk of falling due to axial instability. These debilitating symptoms are further complicated by degenerative or osteoporotic changes of the spine, which are evidenced to be common in patients with PD. Magnetic Resonance Imaging (MRI) described paraspinal muscle signal abnormalities and fatty replacement in camptocormia patients [5,6], while spinal erector electromyogram shows motor unit reductions [6]. Camptocormia can be an idiopathic condition, but can also be associated with numerous diseases like spinal or metabolic disorders, neuromuscular and movement disorders [2,4]. Camptocormia in PD patients did not show significant improvement with levodopa treatment [4,7]. Conservative treatment for camptocormia, such as psychotherapy, physiotherapy, drugs and botulinum toxin injections are limited and usually futile [8]. Surgical treatment includes bilateral pallidal (GPI) or bilateral Subthalamic Nucleus (STN) DBS [8]. Several reports showed successful bilateral pallidal and bilateral subthalamic nucleus stimulation leading to alleviation of camptocormia in PD patients [7,9-13], and patients without PD [14]. Reports of success after STN or GPI stimulation support the important role of the basal ganglia in axial posture control [13]. However, outcome results are inconsistent, especially STN DBS data. The aim of this study was to determine the efficacy of bilateral STN DBS in alleviating the degree of camptocormia in two PD patients by measuring the thoracolumbar angle preoperatively and on pre-defined postoperative follow up.

PATIENTS AND METHODS

Two patients suffering from PD associated with camptocormia underwent operative treatment. The Thoracolumbar Flexion Angle (TLA) was assessed before and after the surgery according to recommended scales for the international survey of DBS: Functional Independence Measure (FIM) instrument, Unified Parkinson Disease Rating Scale – UPDRS, especially motor score and Activities Of Daily Living (ADL) and levodopa dosage. TLA was measured from the lateral view of the patient and it is the angle between the thoracolumbar spine and a vertical line [Figure 1]. Both patients (67 year old female and 66 year old male) were diagnosed with an advanced PD and severe camptocormia at least ten years prior to operation. It started with unilateral tremor, rigidity and dyskinesia and was characterized by bilateral spreading. Over the last 3 years camptocormia progressed. Pharmacotherapy showed poor effect on PD and camptocormia management. Therefore, patient’s life quality was significantly decreased. Preoperatively, patients UPDRS III score, TLA degrees and UPDRS ADL score were recorded [Table 1].

Both patients underwent bilateral stereotactic Subthalamic Nucleus Deep Brain Stimulation (STN DBS) surgery. In a local anesthesia, a Leksell frame was fixed on the patient’s head and Multi-Slice Computed Tomography (MSCT) scan was performed (slides thickness 0,75 mm). Aftewards, the MSCT scan was merged with a preoperative MRI T2 sequences (slides thickness 1,5 mm) using Medtronic Stealth Station TREON plus Surgical Navigation. Target point (STN bilaterally) was defined alongside with the entry point, whereupon Medtronic electrodes (lead model 3389) were implanted bilaterally in the STN. The target point was determined according to the anterior (AC) and posterior (PC) commissures as follows: for the first patient 16.5 millimeters (mm) posterior from the AC, 14.5 mm
The UPDRS ADL score improved from 39 to 10. FIM score improved year after the surgery. UPDRS III score improved from 52 to 16, and after the initial programming, one week postoperatively. The degree of thoracolumbar flexion substantially decreased in both patients. In female patient TLA was decreasing over time; 20° after the first month, 15° after 3 months, 13° after 6 months, and finally 10° after 12 months, respectively. Reduced TLA implicated posture improvement for more than 85% and increased life quality in our patients. It should be mentioned that in several studies [1,10] beneficial effect of STN DBS didn’t occur within all patients included. The efficacy of DBS in PD patients with camptocormia seems to depend whether camptocormia is caused by predominant basal ganglia dysfunction or myopathy [18]. Camptocormia caused by myopathy is more frequent and doesn’t respond to DBS, unlike camptocormia caused by basal ganglia dysfunction [18]. Patients who do not respond to DBS treatment should be screened for other camptocormia causes [18]. Also, the efficacy of STN DBS depends on the duration of camptocormia. Patients with shorter duration of camptocormia experience a substantial improvement in their TLA [13,17].

RESULTS

PD symptoms and camptocormia showed rapid improvement after the initial programming, one week postoperatively. The degree of thoracolumbar flexion substantially decreased in both patients. In female patient TLA was decreasing over time; 20° after the first month, 16° after 3 months, 13° after 6 postoperative months and finally 10° a year after the surgery. UPDRS III score improved from 52 to 16, and the UPDRS ADL score improved from 39 to 10. FIM score improved from 70 to 116 postoperatively. Levodopa daily dose was reduced from 1000 mg preoperatively to 645 mg postoperatively [Table 1]. In male patient TLA was decreasing over time; 15° after the first month, 13° after 3 months and 10° after 6 months. UPDRS III score improved from 44 to 20 postoperatively, UPDRS ADL score improved from 30 to 10, FIM improved to 118 postoperatively. Levodopa daily dose was reduced from 1860 mg preoperatively to 1000 mg postoperatively [Table 1]. Quality of life increased significantly in both patients, pain and sleep problems included. There were no postoperative complications and the positions of implanted electrodes were within STN in both patients. The stimulation parameters were slightly changed on the follow-ups if the patients experienced dyskinesia or other adverse effects.

DISCUSSION

DBS is widely accepted form of therapy for PD patients, especially in patients with pharmacy resistant PD [15]. Unlike several papers reporting beneficial effect of DBS on motor symptoms and dyskinesia in PD patients, there are only few reports showing the effect of DBS in PD patients with camptocormia [1,11,13,16-18]. Bilateral STN DBS showed significant improvement of camptocormia with a substantial improvement of the TLA of around 78 ± 9.1% [12], which is consistent with our result. Like in other studies, our patients showed major improvement after the DBS procedure. Their results in UPDRS III “off medication” are more than 50% improved after 6 and 12 months, respectively. A substantial improvement was observed in their UPDRS III “on medication” with a decline from 39 and 30 preoperatively to 10 postoperatively. TLA in both patients notably reduced to only 10° for about 6 and 12 months after the operation, respectively. Reduced TLA implicates posture improvement for more than 85% and increased life quality in our patients. It should be mentioned that in several studies [1,10] beneficial effect of STN DBS didn’t occur within all patients included. The efficacy of DBS in PD patients with camptocormia seems to depend whether camptocormia is caused by predominant basal ganglia dysfunction or myopathy [18]. Camptocormia caused by myopathy is more frequent and doesn’t respond to DBS, unlike camptocormia caused by basal ganglia dysfunction [18]. Patients who do not respond to DBS treatment should be screened for other camptocormia causes [18]. Also, the efficacy of STN DBS depends on the duration of camptocormia. Patients with shorter duration of camptocormia experience a beneficial DBS effect [19]. Reports of posture improvement in PD patients with bilateral STN or GPi DBS surgical procedure confirm that basal ganglia has a great role in posture and gait control [20,21]. Besides STN, the GPi can be considered an alternative target for PD patients with camptocormia, because it’s assumed that most STN efferent neurons send axons that simultaneously innervate the GPi [20,21]. There are studies confirming that bilateral GPi DBS can alleviate the severity of camptocormia in PD patients [13,17].

CONCLUSION

Although results may vary from excellent improvement to no improvement at all, STN DBS should be considered as a potential treatment option for PD patients with camptocormia. Majority reports of bilateral STN and GPi DBS in PD patients with camptocormia speak in favor of successful control of axial posture in these patients. Further and bigger studies are needed to conclude which PD patients are candidates for bilateral STN or GPi stimulation and what kind of screening should they undergo to determine if they are appropriate candidates for STN or GPi DBS.

Table 1: Follow up of the two PD patients with camptocormia who underwent DBS.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (year)/sex</th>
<th>Duration of disease (year)</th>
<th>Follow-up after surgery (months)</th>
<th>UPDRS III off medication</th>
<th>Preoperatively</th>
<th>Postoperatively (on follow ups)</th>
<th>Improvement (%)</th>
<th>UPDRS III on medication</th>
<th>Preoperatively</th>
<th>Postoperatively</th>
<th>Levodopa daily dose (mg)</th>
<th>Preoperatively</th>
<th>Postoperatively</th>
<th>Thoracolumbar angle TLA (degrees)</th>
<th>Preoperatively</th>
<th>Postoperatively (follow ups)</th>
<th>Improvement (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>67 / F</td>
<td>15</td>
<td>1 / 3 / 6 / 12</td>
<td>52</td>
<td>22 / 18 / 18 / 16</td>
<td>1000 / 1645 / 1000</td>
<td>75% / 80% / 83.75% / 87.5%</td>
<td>39 / 30</td>
<td>80 / 50 / 65</td>
<td>20 / 16 / 18 / 16</td>
<td>75% / 80% / 83.75% / 87.5%</td>
<td>75% / 80% / 83.75% / 87.5%</td>
<td>75% / 80% / 83.75% / 87.5%</td>
<td>75% / 80% / 83.75% / 87.5%</td>
<td>39 / 30</td>
<td>80 / 50 / 65</td>
<td>20 / 16 / 18 / 16</td>
</tr>
</tbody>
</table>
REFERENCES


